Industry research
Dialysis & Renal Care (EU)
Scope
Europe
Companies
29
Key takeaways
What is the scope of this industry report?
The European dialysis and renal care industry comprises businesses that provide patient treatment services and manufacture equipment used to treat kidney diseases. Kidney diseases impair the kidney's ability to filter waste from the blood, resulting in the accumulation of waste and toxins that damage multiple organ systems. Such diseases can be acute, arising from a sudden event where kidney function is rapidly affected (e.g. major surgery, trauma), or chronic, resulting from long-term conditions such as diabetes and uncontrolled hypertension that progressively damage kidney function over years (WHO, April 2026). Within this context, dialysis equipment refers to the machines, consumables and disposables used to perform kidney replacement therapy (KRT), while renal care services is a broader term that encompasses the clinics, hospitals and home-care providers delivering dialysis, patient monitoring and ongoing clinical support. Kidney transplantation is excluded from the scope of this research, as it represents an alternative treatment to dialysis. Based on players’ offerings, we segmented the market into: (i) renal care equipment and (ii) dialysis and renal treatment services.
What does the Dialysis & Renal Care landscape look like in Europe?
The global renal care equipment market is highly consolidated. Fresenius Medical Care held ~35% of the global market for dialysis products in 2025 (flat versus 2024), with a leading >40% share in HD products and ~14% in PD products (Fresenius Medical Care, July 2026). Zooming into Europe, sizeable players also include Pollet Group and Santé Cie Group (both generating >€500m in annual revenue), as well as international developers with a considerable European presence, such as Nipro (JP) and Vantive (US; MedTech World, May 2026; Nipro, May 2025). The competitive market landscape is shaped by financial sponsors' buy-and-build strategies. For example, Numantec Group scaled from an initial 2021 investment by White Bridge Investments into a platform with ~600 employees through a series of add-on acquisitions, including Health Line, PHS Medical and DBM. After the roll-up, Numantec Group was sold in 2026 at a valuation of ~€700m to Goldman Sachs Asset Management (Euronext, July 2026). In parallel, Ardian-backed Santé Cie Group continues to grow through bolt-on acquisitions, including MHComm and Locapharm’s France in-home medical service business in 2025 (CF News, July 2025).
What is the level of investor activity in the Dialysis & Renal Care market landscape in Europe?
Investor-led interest has been high, with ~62% of identified assets being backed by financial sponsors (August 2026). Investors are primarily attracted by (i) structural demand growth from rising diabetes and hypertension prevalence alongside population ageing, (ii) technological advances in home-based dialysis and remote monitoring, unlocking capacity expansion given Europe's home dialysis penetration remains low, as well as (iii) rising public healthcare expenditure and R&D subsidies, lowering capital barriers for equipment and service innovation. Deterring factors for investment mainly relate to (i) government-controlled reimbursement policies, limiting cost pass-through amid rising labour and consumables inflation, (ii) skilled dialysis nurse shortages that constrain service capacity, as well as (iii) rising pre-emptive transplant rates and SGLT2 inhibitor adoption delaying dialysis initiation
What are the key ESG considerations in Europe's Dialysis & Renal Care industry?
ESG topics in the European dialysis and renal care industry primarily relate to environmental and social challenges. Environmental concerns stem mainly from the widespread use of single-use plastic consumables (e.g. blood tubing sets, dialysate bags and needles), which generate substantial volumes of medical waste, as well as from the high water intensity of in-centre HD treatments. To mitigate these impacts, incumbents adopt reusable packaging and recycling initiatives, invest in more sustainable product designs, upgrade reverse osmosis water treatment systems and recycle reject water to lower overall resource use. From a social perspective, uneven access to dialysis infrastructure across Eastern and Western Europe remains a core concern, as does workforce strain amid tightening nephrology staffing. To address these issues, identified players invest in clinician training and infrastructure development in underserved markets, alongside adopting remote-monitoring technologies and reducing administrative burden on physicians to allow greater focus on clinical care.
Company benchmarking
Market growth
The global dialysis patient population rose from ~4.3m in 2024 to ~4.5m in 2025 (+4.7% YoY) and is expected to reach ~7m by 2035. Within the dialysis equipment market, HD dialysers remained the largest product group, with worldwide sales volumes of ~450m units in 2025, up from ~430m in 2024 (+4.7% YoY; Fresenius Medical Care, July 2026)
Statista (June 2024) projects the global dialysis equipment market to grow from ~$20.0bn in 2023 to ~$30.1bn in 2032 (+4.6% CAGR 2023-2032)
Positive drivers
Rising diabetes prevalence (up ~22% between 2012-2022) and hypertension (affecting ~25% of adults in Europe), alongside population ageing, are expanding Europe's chronic kidney disease patient pool. As most of these patients progress to kidney failure, this creates structurally recurring demand for KRT therapy, supporting high revenue visibility for dialysis service providers and consumables suppliers (Fresenius Medical Care, July 2026; European Commission, December 2025)
Technological advances in home-based dialysis and remote monitoring enable service providers to expand patient coverage without proportional investment in centre capacity, improving operating leverage. Europe’s home dialysis penetration remains low at ~7% (including both home-based PD and HD), versus ~47% in Australia and ~74% in New Zealand, indicating substantial adoption headroom and a structural tailwind for equipment and service providers (ERA, August 2025; European Journal of Internal Medicine, July 2025)
Rising public healthcare expenditure (e.g. the EU’s ~€43bn investments in healthcare) and targeted R&D subsidies (e.g. the EU’s ~€2.5m grants to facility home HD development) support service capacity expansion and equipment innovation. These initiatives can reduce capital barriers to deploy and install next-generation equipment for providers, while R&D support lowers development risks and accelerates product commercialisation for equipment developers (European Commission, May 2026; European Commission, June 2025)
Negative drivers
Government-controlled reimbursement policies create margin pressure for dialysis service providers, with reimbursement rates and payment structures varying materially across European markets. Rising labour, logistics and consumables costs may outpace reimbursement rate adjustments, limiting service providers’ ability to pass through cost inflation and pressuring profitability ratios (Fresenius Medical Care, February 2026)
Skilled dialysis nurse shortages may constrain service capacity, as in-centre HD remains more labour-intensive than PD and other home modalities. Nurse labour requirements per patient are ~3.4x higher for in-centre HD than PD and ~3.3x higher than home-based HD, increasing renal service providers’ exposure to workforce shortages as HD demand rises (ERA, June 2024)
Pre-emptive transplant rates in Europe rose from ~4% in 2022 to ~6% in 2023, while SGLT2 inhibitors (early-stage CKD therapies) are reported to reduce kidney failure risk by ~34%. These interventions may delay or prevent dialysis initiation, limiting the long-term growth pool for dialysis services and consumables (ERA, May 2026; Cleveland Clinic, November 2025; ERA, December 2024)
Fill out the form to request your copy of the Dialysis & Renal Care (EU) industry report
With the full report, you’ll gain access to:
Detailed assessments of the market outlook
Insights from c-suite industry executives
A clear overview of all active investors in the industry
An in-depth look into 29 private companies, incl. financials, ownership details and more.
A view on all 180 deals in the industry
ESG assessments with highlighted ESG outperformers
Discover hundreds of niche industry reports on Gain
Deep dive into additional industries to understand their market outlook, positive and negative drivers, and more!
